Barclays PLC Purchases 44,903 Shares of TScan Therapeutics, Inc. (NASDAQ:TCRX)

Barclays PLC increased its holdings in TScan Therapeutics, Inc. (NASDAQ:TCRX) by 341.1% during the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 58,067 shares of the company’s stock after buying an additional 44,903 shares during the period. Barclays PLC owned 0.11% of TScan Therapeutics worth $289,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Great Point Partners LLC boosted its position in shares of TScan Therapeutics by 8.0% during the 3rd quarter. Great Point Partners LLC now owns 1,016,375 shares of the company’s stock valued at $5,062,000 after acquiring an additional 75,544 shares during the last quarter. Geode Capital Management LLC lifted its position in TScan Therapeutics by 8.1% during the third quarter. Geode Capital Management LLC now owns 973,466 shares of the company’s stock valued at $4,849,000 after purchasing an additional 72,967 shares during the last quarter. Checkpoint Capital L.P. bought a new stake in TScan Therapeutics during the third quarter valued at approximately $4,110,000. State Street Corp grew its stake in TScan Therapeutics by 24.4% in the 3rd quarter. State Street Corp now owns 756,499 shares of the company’s stock worth $3,767,000 after buying an additional 148,414 shares in the last quarter. Finally, abrdn plc increased its holdings in shares of TScan Therapeutics by 27.2% in the 3rd quarter. abrdn plc now owns 371,655 shares of the company’s stock worth $1,851,000 after buying an additional 79,511 shares during the last quarter. 82.83% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research analysts recently issued reports on TCRX shares. HC Wainwright reiterated a “buy” rating and issued a $15.00 target price on shares of TScan Therapeutics in a research report on Wednesday, December 11th. Needham & Company LLC reiterated a “buy” rating and issued a $11.00 price objective on shares of TScan Therapeutics in a report on Wednesday, December 11th. Finally, Wedbush reissued an “outperform” rating and set a $7.00 price objective on shares of TScan Therapeutics in a report on Monday, December 23rd.

TScan Therapeutics Price Performance

Shares of NASDAQ:TCRX opened at $2.40 on Tuesday. The company has a quick ratio of 9.56, a current ratio of 9.56 and a debt-to-equity ratio of 0.13. The stock has a market cap of $128.09 million, a PE ratio of -2.26 and a beta of 0.91. The company’s fifty day moving average is $3.56 and its 200 day moving average is $5.01. TScan Therapeutics, Inc. has a 52 week low of $2.38 and a 52 week high of $9.69.

TScan Therapeutics (NASDAQ:TCRX) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.25) EPS for the quarter, topping the consensus estimate of ($0.28) by $0.03. The firm had revenue of $1.05 million for the quarter, compared to the consensus estimate of $2.86 million. TScan Therapeutics had a negative return on equity of 58.72% and a negative net margin of 1,188.88%. Research analysts anticipate that TScan Therapeutics, Inc. will post -1.12 earnings per share for the current year.

TScan Therapeutics Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.